Evidence supporting the use of: Thymus polypeptide
For the health condition: Tuberculosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Thymus polypeptide, also known as thymosin or thymic extract, has been studied as an immunomodulatory agent, particularly in the context of infectious diseases like tuberculosis (TB). The rationale for its use is based on its ability to enhance cell-mediated immunity, which is crucial in the host response to Mycobacterium tuberculosis. Several clinical trials, primarily from the 1990s and early 2000s, have evaluated thymic peptides—such as thymosin alpha-1 and thymopentin—as adjunctive therapies in TB. Some studies reported improved lymphocyte function, enhanced delayed-type hypersensitivity responses, and, in a few cases, more rapid sputum conversion when thymic peptides were combined with standard anti-TB therapy. However, these studies were typically small, sometimes lacked rigorous controls, and results were not always consistent. Systematic reviews and major TB treatment guidelines do not currently recommend thymus polypeptides as a standard adjunctive therapy, citing insufficient high-quality evidence for clinical benefit. The use of thymus polypeptide in TB is therefore justified by some preliminary scientific studies indicating possible immunomodulatory benefits, but strong, confirmatory evidence from large, well-controlled trials is lacking. As such, the evidence supporting its use in TB is limited and not robust enough for routine clinical recommendation.

More about Thymus polypeptide
More about Tuberculosis

Products containing Thymus polypeptide

We currently have no products on Vitabase that contain this ingredient.